ImmunoCellular Therapeutics Ltd Company Profile (NYSEMKT:IMUC)

About ImmunoCellular Therapeutics Ltd

ImmunoCellular Therapeutics Ltd logoImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NYSEMKT
  • Symbol: IMUC
  • CUSIP: 45253610
Key Metrics:
  • Previous Close: $2.72
  • 50 Day Moving Average: $2.44
  • 200 Day Moving Average: $3.87
  • 52-Week Range: $3,444,000.00 - $1.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.52
  • P/E Growth: 0.00
  • Market Cap: $9.37M
  • Outstanding Shares: 3,444,000
  • Beta: 0.68
Additional Links:
Companies Related to ImmunoCellular Therapeutics Ltd:

Analyst Ratings

Consensus Ratings for ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $2.00

Analysts' Ratings History for ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
Show:
DateFirmActionRatingPrice TargetDetails
11/11/2016Maxim GroupDowngradeBuy -> HoldView Rating Details
11/12/2015Roth CapitalReiterated RatingBuy$3.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2017        
11/10/2016Q316($0.04)($0.04)ViewN/AView Earnings Details
8/22/2016Q2($0.07)($0.06)ViewListenView Earnings Details
5/12/2016Q116($0.07)($0.06)ViewListenView Earnings Details
3/30/2016Q415($0.06)($0.05)ViewListenView Earnings Details
11/10/2015Q315($0.06)($0.04)ViewN/AView Earnings Details
8/6/2015Q215($0.05)($0.03)ViewN/AView Earnings Details
5/11/2015Q1($0.02)($0.02)ViewN/AView Earnings Details
3/9/2015Q414($0.05)($0.04)ViewN/AView Earnings Details
11/10/2014Q314($0.06)($0.03)ViewN/AView Earnings Details
8/11/2014($0.06)($0.04)ViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.05)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.08)($0.05)ViewN/AView Earnings Details
3/5/2013Q4 2012($0.08)$0.01ViewN/AView Earnings Details
11/12/2012Q312($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
Current Year EPS Consensus Estimate: $-7.20 EPS
Next Year EPS Consensus Estimate: $-5.20 EPS

Dividends

Dividend History for ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2015Andrew GengosCEOBuy10,000$0.44$4,400.00View SEC Filing  
2/18/2015Andrew GengosCEOBuy41,333$0.60$24,799.80View SEC Filing  
2/18/2015Andrew GengosCEOBuy41,333$0.60$24,799.80View SEC Filing  
2/18/2015Anthony GringeriVPBuy30,000$0.60$18,000.00View SEC Filing  
2/18/2015David FractorVPBuy16,667$0.60$10,000.20View SEC Filing  
8/21/2014Anthony GringeriVPBuy11,000$0.91$10,010.00View SEC Filing  
8/14/2014Andrew GengosCEOBuy10,000$0.90$9,000.00View SEC Filing  
12/20/2013Gary TitusDirectorBuy18,000$0.78$14,040.00View SEC Filing  
12/18/2013Andrew GengosCEOBuy27,000$0.72$19,440.00View SEC Filing  
10/21/2013John S YuInsiderSell267,387$2.91$778,096.17View SEC Filing  
8/29/2013James BenderVPSell14,203$2.87$40,762.61View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
DateHeadline
News IconImmunoCellular Therapeutics, Ltd. (:IMUC) Losing Ground in Session - Aiken Advocate (NYSEMKT:IMUC)
aikenadvocate.com - February 16 at 4:46 PM
News Icon13 hedge funds sold their entire positions in ImmunoCellular Therapeutics, Ltd. (IMUC) - Post Analyst (NYSEMKT:IMUC)
postanalyst.com - February 15 at 9:04 PM
prnewswire.com logoSAVSU Technologies Provides Performance Update on evo® Cold Chain 2.0™ System in ImmunoCellular ... - PR Newswire (press release) (NYSEMKT:IMUC)
www.prnewswire.com - February 15 at 12:19 AM
News IconImmunoCellular Therapeutics, Ltd. (IMUC) Valuation According To Analysts - UK Market News (NYSEMKT:IMUC)
www.ukmarketnews.co.uk - February 1 at 11:39 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at ImmunoCellular Therapeutics, Ltd. (:IMUC) - Nelson Research (NYSEMKT:IMUC)
nelsonobserver.com - January 29 at 4:03 AM
News IconBargain or Bait? Stock Update on ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - January 27 at 7:53 PM
News IconStock Cutting The Mustard Mid-Session: ImmunoCellular ... - Aiken Advocate (NYSEMKT:IMUC)
aikenadvocate.com - January 25 at 7:21 PM
News IconEnlivened Volatility Spotted in Shares of ImmunoCellular Therapeutics, Ltd. (:IMUC) - Wall Street Beacon (NYSEMKT:IMUC)
wsbeacon.com - January 25 at 7:21 PM
News IconShould You Sell ImmunoCellular Therapeutics, Ltd. Based On Current Broker Views? - NewsDen (NYSEMKT:IMUC)
newsden.net - January 24 at 11:39 PM
News IconAre Discerning Investors Interested in These Shares ... - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - January 20 at 12:42 AM
News IconAmplified Volatility Spotted in Shares of ImmunoCellular Therapeutics, Ltd. (:IMUC) - Wall Street Beacon (NYSEMKT:IMUC)
wsbeacon.com - January 19 at 7:40 PM
News IconPumping the Brakes as Stock Dragged Lower Mid-Session: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Wall Street Beacon (NYSEMKT:IMUC)
wsbeacon.com - January 19 at 4:27 AM
News IconShooting From the Hip, Stock Reaches Most Volatile List: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Wall Street Beacon (NYSEMKT:IMUC)
wsbeacon.com - January 19 at 4:27 AM
News IconPrimed for Breakout or Bust? A look at ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - January 18 at 4:12 AM
News IconStock Momentum Skidding to a Halt For ImmunoCellular Therapeutics, Ltd. (:IMUC) - Wall Street Beacon (NYSEMKT:IMUC)
wsbeacon.com - January 18 at 4:12 AM
News IconA Keen Look at These Shares: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - January 14 at 5:08 AM
News IconAre There Any Catalysts to Propel This Stock Forward: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - January 12 at 6:24 PM
News IconStock Getting Tripped Up In Session: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Wall Street Beacon (NYSEMKT:IMUC)
wsbeacon.com - January 12 at 4:33 AM
News IconImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC): What's Behind The Run? - Insider Financial (NYSEMKT:IMUC)
www.insiderfinancial.com - January 12 at 4:33 AM
News IconStock Reaching Most Volatile List Today: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Wall Street Beacon (NYSEMKT:IMUC)
wsbeacon.com - January 12 at 4:33 AM
News IconImmunoCellular Therapeutics, Ltd. (IMUC) Under Analyst Spotlight - UK Market News (NYSEMKT:IMUC)
www.ukmarketnews.co.uk - January 7 at 7:45 PM
News IconPeering into Recent Action from ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - January 6 at 6:33 PM
News IconIs This a Sensible Stock at Current Levels: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - January 5 at 7:14 PM
News IconWells Fargo & Company (WFC) Position Increased by 1st Global Advisors Inc (NYSEMKT:IMUC)
xboxonezone.com - January 4 at 6:49 PM
News IconPlacing the Bulls-Eye Focus on ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - January 3 at 8:59 PM
News IconInvestors Keen on a Bargain are Looking at ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - December 28 at 10:52 PM
News IconCheap Stock Alert on ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - December 28 at 10:51 AM
News IconStock in the Limelight: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - December 28 at 10:51 AM
live-pr.com logoNew Market Research Report: ImmunoCellular Therapeutics, Ltd. (IMUC) - Financial and Strategic SWOT Analysis Review (NYSEMKT:IMUC)
www.live-pr.com - December 28 at 10:51 AM
News IconWhich Direction is This Stock Headed? Update on ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - December 22 at 4:47 AM
News IconKeen Investors Taking a Look at ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - December 21 at 9:17 AM
bizjournals.com logoImmunoCellular names new CEO (NYSEMKT:IMUC)
www.bizjournals.com - December 15 at 11:33 PM
smarteranalyst.com logoCompany Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Names Anthony Gringeri CEO - Smarter Analyst (NYSEMKT:IMUC)
www.smarteranalyst.com - December 14 at 11:37 PM
seekingalpha.com logoNew chief at ImmunoCellular Therapeutics (NYSEMKT:IMUC)
seekingalpha.com - December 14 at 8:15 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: ImmunoCellular Therapeutics, Ltd. (:IMUC) - Prospect Journal (NYSEMKT:IMUC)
prospectjournal.com - December 6 at 5:46 AM
News IconImmunoCellular Therapeutics, Ltd. (IMUC) Analyst Recommendation - NewsDen (NYSEMKT:IMUC)
newsden.net - December 5 at 3:20 PM
News IconPenny Stock Spotlight: Focusing on ImmunoCellular Therapeutics, Ltd. (:IMUC) - Duncan Research (NYSEMKT:IMUC)
www.duncanindependent.com - November 23 at 5:40 PM
News IconShares Sink Lower with a Gap Pre-Market: ImmunoCellular Therapeutics, Ltd. (:IMUC) - CSZ News (NYSEMKT:IMUC)
cincysportszone.com - November 22 at 5:40 PM
4-traders.com logoIMMUNOCELLULAR THERAPEUTICS LTD : REVERSE SPLIT: 1 of 40 (NYSEMKT:IMUC)
www.4-traders.com - November 21 at 5:59 PM
finance.yahoo.com logoImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in Newly … (NYSEMKT:IMUC)
finance.yahoo.com - November 21 at 5:59 PM
News IconActive Stocks in Frontline Rating: AstraZeneca PLC (NYSE:AZN), ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) - Seneca Globe (NYSEMKT:IMUC)
www.senecaglobe.com - November 21 at 10:45 AM
streetinsider.com logoImmunoCellular Therapeutics (IMUC) Announces Presentation of Updated ICT-107 Phase 2 Data in GBM - StreetInsider.com (NYSEMKT:IMUC)
www.streetinsider.com - November 21 at 10:45 AM
News IconPenny Stock Focus: Narrowing the Lens On ImmunoCellular Therapeutics, Ltd. (:IMUC) - Duncan Research (NYSEMKT:IMUC)
www.duncanindependent.com - November 19 at 8:09 AM
News IconPenny Stock Making Waves: Taking a Second Look at ImmunoCellular Therapeutics, Ltd. (:IMUC) - Duncan Research (NYSEMKT:IMUC)
www.duncanindependent.com - November 17 at 5:11 PM
prnewswire.com logoImmunoCellular Therapeutics Announces One-for-Forty Reverse ... - PR Newswire (press release) (NYSEMKT:IMUC)
www.prnewswire.com - November 16 at 9:13 AM
publicnow.com logoImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split (NYSEMKT:IMUC)
www.publicnow.com - November 16 at 9:13 AM
News IconPenny Stock Making News: Putting the Microscope On ImmunoCellular Therapeutics, Ltd. (:IMUC) - Duncan Research (NYSEMKT:IMUC)
www.duncanindependent.com - November 15 at 9:07 AM
finance.yahoo.com logoEdited Transcript of IMUC earnings conference call or presentation 10-Nov-16 10:00pm GMT (NYSEMKT:IMUC)
finance.yahoo.com - November 14 at 9:42 AM
News IconPenny Stock News: Looking Closer At ImmunoCellular Therapeutics, Ltd. (:IMUC) - Duncan Research (NYSEMKT:IMUC)
www.duncanindependent.com - November 12 at 8:06 AM
smarteranalyst.com logoStock Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Reports 3Q:16 Results and Provides Research and ... - Smarter Analyst (NYSEMKT:IMUC)
www.smarteranalyst.com - November 10 at 5:05 PM

Social

What is ImmunoCellular Therapeutics Ltd's stock symbol?

ImmunoCellular Therapeutics Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "IMUC."

Where is ImmunoCellular Therapeutics Ltd's stock going? Where will ImmunoCellular Therapeutics Ltd's stock price be in 2017?

1 equities research analysts have issued 12-month price targets for ImmunoCellular Therapeutics Ltd's shares. Their predictions range from $2.00 to $2.00. On average, they anticipate ImmunoCellular Therapeutics Ltd's stock price to reach $2.00 in the next twelve months.

When will ImmunoCellular Therapeutics Ltd announce their earnings?

ImmunoCellular Therapeutics Ltd is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.

Who owns ImmunoCellular Therapeutics Ltd stock?

ImmunoCellular Therapeutics Ltd's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.83%).

Who sold ImmunoCellular Therapeutics Ltd stock? Who is selling ImmunoCellular Therapeutics Ltd stock?

ImmunoCellular Therapeutics Ltd's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy ImmunoCellular Therapeutics Ltd stock?

Shares of ImmunoCellular Therapeutics Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ImmunoCellular Therapeutics Ltd stock cost?

One share of ImmunoCellular Therapeutics Ltd stock can currently be purchased for approximately $2.72.


Last Updated on 2/20/2017 by MarketBeat.com Staff